T-cell Hematologic Malignancies

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS research · 2026-03-04
Clinical Trial Update: Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies [Phase 2]
Phase II study evaluating CD5 CAR-engineered IL-15-transduced cord blood-derived NK cells combined with lymphodepleting chemotherapy for agg…